• Adelina Pellicer, Joan Riera, Paloma Lopez-Ortego, María Carmen Bravo, Rosario Madero, Jesús Perez-Rodriguez, Carlos Labrandero, Jose Quero, Antonio Buño, Luis Castro, Rubin Lubomirov, and Fernando Cabañas.
• Department of Neonatology, La Paz University Hospital, Madrid, Spain. apellicer.hulp@salud.madrid.org
• Pediatr. Res. 2013 Jan 1; 73 (1): 95-103.

BackgroundInodilators are routinely used in cardiovascular surgery with cardiopulmonary bypass (CPB). Information regarding safety and tolerability of the novel molecule, levosimendan (LEVO), in newborns is anecdotal; no pharmacokinetic data in this population are available.MethodsThis was a phase I, randomized, and blinded study. Neonates undergoing surgical repair for congenital heart defects received stepwise dose increases of milrinone (MR; 0.5-1 μg/kg/min, n = 9) or LEVO (0.1-0.2 μg/kg/min, n = 11) as an i.v. continuous infusion, starting before CPB. Infants had continuous, time-locked, physiological, and near-infrared spectroscopy (NIRS) (cerebral and peripheral) recordings during the first 24 h, and at 48 and 96 h postsurgery. Serial biochemistry and pharmacokinetic studies were performed.ResultsDuring the first 24 h postsurgery, patients showed time-related, group-independent increased cerebral tissue oxygenation and decreased diastolic blood pressure; in addition, group-dependent differences in heart rate and peripheral perfusion were found. Early postsurgery, MR-treated infants showed lower pH, higher glycemia, and higher inotrope score. The groups differed in cerebral NIRS-derived variables from 24 to 96 h. Study drug withdrawal at 96 h was more frequent with LEVO. LEVO intermediate metabolites were detected in plasma at day 14 after surgery.ConclusionLEVO is well tolerated in critically ill neonates. LEVO may have advantages over MR in terms of the dosing regimen.

31 keywords...

hide…